Research Analysts Set Expectations for Illumina Q1 Earnings

Illumina, Inc. (NASDAQ:ILMN) – Leerink Partnrs upped their Q1 2025 EPS estimates for Illumina in a report released on Tuesday, January 7th. Leerink Partnrs analyst P. Souda now forecasts that the life sciences company will earn $0.85 per share for the quarter, up from their prior forecast of $0.84. The consensus estimate for Illumina’s current full-year earnings is $4.11 per share.

Illumina (NASDAQ:ILMN) last released its earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.26. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The firm had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.08 billion. During the same quarter last year, the business posted $0.33 earnings per share. The firm’s revenue was down 3.5% on a year-over-year basis.

Other research analysts also recently issued research reports about the stock. Royal Bank of Canada increased their price objective on shares of Illumina from $252.00 to $254.00 and gave the company an “outperform” rating in a report on Tuesday, November 5th. JPMorgan Chase & Co. raised their price target on Illumina from $125.00 to $140.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Citigroup cut Illumina from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $190.00 to $165.00 in a report on Wednesday, December 11th. Leerink Partners raised their target price on shares of Illumina from $160.00 to $200.00 and gave the company an “outperform” rating in a report on Thursday, October 17th. Finally, Barclays upped their price target on shares of Illumina from $135.00 to $145.00 and gave the company an “equal weight” rating in a research note on Tuesday, November 5th. Eight research analysts have rated the stock with a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $165.95.

Illumina Price Performance

ILMN stock opened at $139.68 on Thursday. The company has a market capitalization of $22.15 billion, a PE ratio of -14.02 and a beta of 1.11. The company’s fifty day moving average price is $141.37 and its 200-day moving average price is $132.08. Illumina has a one year low of $100.08 and a one year high of $156.66. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.85 and a current ratio of 2.43.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Empowered Funds LLC boosted its stake in shares of Illumina by 1.7% during the third quarter. Empowered Funds LLC now owns 3,960 shares of the life sciences company’s stock valued at $516,000 after purchasing an additional 66 shares in the last quarter. Caprock Group LLC lifted its holdings in Illumina by 3.0% during the third quarter. Caprock Group LLC now owns 2,884 shares of the life sciences company’s stock worth $376,000 after buying an additional 83 shares during the period. Integrated Advisors Network LLC boosted its position in Illumina by 2.0% during the 3rd quarter. Integrated Advisors Network LLC now owns 4,484 shares of the life sciences company’s stock valued at $585,000 after acquiring an additional 90 shares in the last quarter. Moors & Cabot Inc. increased its holdings in shares of Illumina by 1.7% in the 3rd quarter. Moors & Cabot Inc. now owns 5,818 shares of the life sciences company’s stock valued at $759,000 after acquiring an additional 95 shares during the period. Finally, Carson Advisory Inc. raised its position in shares of Illumina by 3.8% in the 3rd quarter. Carson Advisory Inc. now owns 2,757 shares of the life sciences company’s stock worth $360,000 after acquiring an additional 102 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.